YKL091C Antibody

What is YKL091C/SFH1 and what is its function in yeast?

YKL091C encodes the SFH1 protein in Saccharomyces cerevisiae, which belongs to the Sec14 protein family. SFH1 functions as a phospholipid transfer protein with the capability to bind various phospholipids, including phosphatidylserine (PS) in vivo . SFH1 plays a crucial role in mitochondrial function, particularly in respiratory growth. The protein's activity is closely related to phospholipid metabolism pathways, especially those involving phosphatidylserine decarboxylase (Psd1), which converts phosphatidylserine to phosphatidylethanolamine in mitochondria .

Recent studies have demonstrated that SFH1 can suppress respiratory growth defects in yeast strains with impaired phosphatidylserine decarboxylase function. This suppression mechanism involves SFH1's phospholipid binding capability, which can be modified through specific mutations to alter its binding affinity and functionality .

What are the primary applications for YKL091C antibody in yeast research?

YKL091C antibody serves multiple critical research applications in yeast studies:

• Protein localization studies: Immunofluorescence microscopy with YKL091C antibody allows visualization of SFH1 subcellular distribution and helps track changes in localization under various experimental conditions .

• Protein expression analysis: Western blotting with YKL091C antibody enables quantification of SFH1 expression levels across different yeast strains, growth conditions, or genetic backgrounds .

• Protein-protein interaction studies: Immunoprecipitation with YKL091C antibody facilitates investigation of SFH1's interaction with other proteins involved in phospholipid metabolism and transfer .

• Chromatin immunoprecipitation (ChIP): For studying potential roles of SFH1 in chromatin-associated processes, particularly relevant since some Sec14-like proteins have been implicated in nuclear functions.

• Validation of genetic modifications: Confirming successful creation of SFH1 mutants, particularly those with tagged versions (such as SFH1-ZZ, SFH1-EGFP, or SFH1-HA) that are commonly used in experimental setups .

How should researchers validate YKL091C antibody specificity?

Methodological validation of YKL091C antibody specificity is essential for reliable experimental results:

• Positive and negative controls: Always include wild-type strains (positive control) and sfh1Δ deletion strains (negative control) in immunoblotting experiments. The absence of signal in the deletion strain confirms antibody specificity .

• Cross-reactivity assessment: Test the antibody against other Sec14 family proteins (SFH2-5, SEC14) to ensure it doesn't cross-react with these homologous proteins. This is particularly important because SFH1 shares structural features with other family members .

• Epitope competition assay: Pre-incubate the antibody with purified recombinant SFH1 protein before immunostaining or immunoblotting. Signal reduction indicates specific binding to SFH1 .

• Multiple antibody validation: When possible, compare results using antibodies raised against different epitopes of SFH1 or using differently tagged versions of SFH1 (such as SFH1-HA or SFH1-ZZ constructs described in the literature) .

• Western blot molecular weight verification: Confirm that the detected protein band appears at the expected molecular weight for SFH1 (~35 kDa) or at the appropriate adjusted weight if using tagged versions .

What are the optimal storage and handling conditions for YKL091C antibody?

For maximum stability and performance of YKL091C antibody:

• Long-term storage: Store antibody aliquots at -80°C to prevent repeated freeze-thaw cycles. For antibodies in glycerol, -20°C storage may be sufficient .

• Working dilutions: Store working dilutions at 4°C for up to two weeks; add preservatives like sodium azide (0.02%) to prevent microbial growth.

• Freeze-thaw minimization: Prepare small single-use aliquots upon receipt to minimize freeze-thaw cycles, which can significantly reduce antibody activity.

• Temperature transitions: Allow antibody to equilibrate to room temperature before opening vials to prevent condensation, which can accelerate degradation.

• Handling precautions: Avoid vortexing antibodies; instead, mix by gentle inversion or flicking the tube to prevent protein denaturation and aggregation.

How can researchers use YKL091C antibody to study SFH1 phospholipid binding properties?

Investigating SFH1's phospholipid binding properties with YKL091C antibody involves several sophisticated approaches:

• Co-immunoprecipitation with lipidomic analysis: Immunoprecipitate SFH1 using YKL091C antibody, then analyze bound phospholipids using mass spectrometry. This allows identification of the phospholipid species that preferentially associate with SFH1 in vivo .

• Mutation impact assessment: Compare phospholipid binding between wild-type SFH1 and variants with specific mutations (such as S175I,T177I; L179W,I196W; or Y113C) using immunoprecipitation with YKL091C antibody followed by lipidomic analysis .

• Competitive binding assays: Perform immunoprecipitation of SFH1 in the presence of varying concentrations of specific phospholipids to determine binding affinities and preferences.

• Subcellular fractionation with immunodetection: Fractionate yeast cells into membrane compartments, then use YKL091C antibody to detect SFH1 distribution, correlating its localization with phospholipid composition of different cellular compartments .

• Fluorescence microscopy with phospholipid probes: Combine immunofluorescence using YKL091C antibody with fluorescent phospholipid probes to visualize co-localization in vivo.

The following table summarizes key SFH1 mutations and their effects on phospholipid binding properties:

What are the key considerations for designing co-immunoprecipitation experiments with YKL091C antibody?

When planning co-immunoprecipitation (co-IP) studies with YKL091C antibody, researchers should consider:

• Lysis buffer optimization: For phospholipid-binding proteins like SFH1, standard RIPA buffers may disrupt lipid interactions. Instead, use gentler buffers with lower detergent concentrations (0.5-1% NP-40 or Triton X-100) and include glycerol (10%) to stabilize protein-lipid complexes .

• Cross-linking protocol development: Consider implementing formaldehyde or DSP (dithiobis[succinimidyl propionate]) cross-linking prior to cell lysis to capture transient interactions, particularly for SFH1's interactions with membrane proteins like Psd1 or Pss1 .

• Control strategies: Include epitope-tagged versions (SFH1-ZZ, SFH1-EGFP, or SFH1-HA) for reciprocal co-IP experiments to validate interactions. This approach helps distinguish true interactions from non-specific binding .

• Subcellular fractionation integration: Perform co-IPs from different subcellular fractions to identify compartment-specific interaction partners, particularly relevant for SFH1 which may interact with different proteins in different cellular locations .

• Detergent screening: Test multiple detergents (digitonin, CHAPS, DDM) to identify optimal conditions that preserve SFH1's native interactions while effectively solubilizing membrane-associated complexes.

How can researchers use YKL091C antibody to investigate SFH1's role in mitochondrial phospholipid transport?

To investigate SFH1's involvement in mitochondrial phospholipid transport pathways:

• Mitochondrial fractionation with immunoblotting: Isolate pure mitochondrial fractions and use YKL091C antibody to detect whether SFH1 associates with mitochondrial membranes under different growth conditions, particularly in respiratory vs. fermentative growth .

• Proximity labeling approaches: Combine BioID or APEX2 proximity labeling with YKL091C antibody detection to identify proteins in close proximity to SFH1 at the mitochondrial surface.

• Genetic interaction analysis: In strains with mutations in mitochondrial phospholipid transport genes (like PSD1), use YKL091C antibody to assess changes in SFH1 localization or abundance, providing insights into compensatory mechanisms .

• In vitro phospholipid transfer assays: Purify SFH1 using YKL091C antibody for immunoaffinity chromatography, then assess its ability to transfer phospholipids between artificial membranes or isolated mitochondria .

• Super-resolution microscopy: Combine immunofluorescence using YKL091C antibody with super-resolution microscopy techniques to visualize SFH1's precise localization relative to mitochondrial membranes and other organelles.

What strategies can resolve contradictory data when studying SFH1 with YKL091C antibody?

When facing contradictory results in SFH1 research using YKL091C antibody:

• Multiple antibody epitope approach: Use antibodies targeting different epitopes of SFH1 to verify results. Discrepancies may arise if certain epitopes become masked in specific protein conformations or complexes .

• Tagged protein verification: Compare results obtained with native SFH1 detection (via YKL091C antibody) to those using tagged versions (SFH1-EGFP, SFH1-HA, SFH1-ZZ) to identify potential artifacts introduced by either approach .

• Growth condition standardization: Systematically vary growth conditions (carbon source, growth phase, temperature) to determine if contradictory results stem from condition-dependent SFH1 behavior.

• Strain background assessment: Test multiple strain backgrounds beyond the commonly used W303-1A or BY4741 to determine if genetic background influences SFH1 function or antibody detection .

• Quantitative analysis implementation: Apply rigorous quantification methods to immunoblots and microscopy images, including statistical analysis across multiple biological replicates to distinguish significant differences from experimental noise.

How can researchers design specificity assays for YKL091C antibody against other SEC14 family members?

Creating robust specificity assays to ensure YKL091C antibody doesn't cross-react with other SEC14 family proteins:

• Recombinant protein panel testing: Express and purify all SEC14 family members (SEC14, SFH1-5) using bacterial expression systems as described in the literature, then test antibody reactivity against each protein via Western blot .

• Epitope sequence alignment analysis: Perform bioinformatic analysis of the epitope region across all SEC14 family members to predict potential cross-reactivity, then validate predictions experimentally.

• Overexpression specificity testing: Generate yeast strains overexpressing each SEC14 family member (using plasmids like YEp181-SFH1, YEp181-SFH2, YEp181-SFH3, YEp181-SFH4, YEp181-SFH5, and YEp181-SEC14), then test antibody reactivity via immunoblotting .

• Knockout strain panel screening: Test the antibody against a panel of yeast strains with individual deletions of each SEC14 family member to confirm the absence of background signal in the sfh1Δ strain while maintaining appropriate signals in other deletion strains.

• Competition assay with peptide library: Synthesize peptides corresponding to homologous regions across SEC14 family members and test their ability to compete with cellular SFH1 for antibody binding.

What are optimal experimental conditions for detecting SFH1 with YKL091C antibody?

For maximum sensitivity and specificity when detecting SFH1:

• Sample preparation optimization: For yeast samples, spheroplasting with zymolyase followed by gentle lysis yields better preservation of SFH1 native structure compared to mechanical disruption methods .

• Extraction buffer composition: Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate) and protease inhibitors (PMSF, protease inhibitor cocktail) in extraction buffers to prevent degradation of SFH1 and preserve its phosphorylation state .

• Immunoblotting conditions: For Western blotting, transfer proteins to PVDF membranes (rather than nitrocellulose) for better retention of hydrophobic proteins like SFH1. Block with 5% BSA rather than milk to prevent non-specific interactions .

• Immunofluorescence fixation: For immunofluorescence microscopy, formaldehyde fixation (4%, 15 minutes) followed by detergent permeabilization preserves SFH1 localization better than methanol fixation.

• Antibody dilution optimization: Typically, use YKL091C antibody at 1:1000 dilution for Western blotting and 1:200 for immunofluorescence, but optimize for each specific application and antibody lot .

How can YKL091C antibody be used to investigate SFH1's interaction with phosphatidylserine synthase?

To explore SFH1's functional relationship with phosphatidylserine synthase (Pss1):

• Co-immunoprecipitation protocol: Immunoprecipitate SFH1 using YKL091C antibody and probe for Pss1 interaction, or conversely, immunoprecipitate tagged Pss1 (Pss1-EGFP) and probe for SFH1 .

• Bimolecular fluorescence complementation: Combine split fluorescent protein tags on SFH1 and Pss1 with YKL091C antibody staining to validate interaction sites and dynamics.

• Genetic interaction analysis: In pss1 mutant backgrounds, use YKL091C antibody to assess changes in SFH1 abundance, modification state, or localization that might indicate functional relationship .

• Microscopy co-localization: Perform dual immunofluorescence with YKL091C antibody and antibodies or fluorescent tags for Pss1 to assess spatial relationships between these proteins .

• In vitro binding assays: Use purified components to assess direct interaction between SFH1 (immunopurified with YKL091C antibody) and Pss1, with and without phospholipid substrates.

How can researchers troubleshoot non-specific binding when using YKL091C antibody?

When encountering non-specific binding with YKL091C antibody:

• Blocking agent optimization: Test different blocking agents (BSA, casein, commercial blocking solutions) at various concentrations to identify optimal conditions that minimize background without compromising specific signal.

• Antibody affinity purification: Consider affinity-purifying YKL091C antibody using recombinant SFH1 protein to improve specificity, particularly for challenging applications like ChIP or immunofluorescence .

• Detergent and salt titration: Systematically increase washing stringency by adjusting detergent (0.1-0.5% Tween-20) and salt (150-500 mM NaCl) concentrations in washing buffers.

• Pre-absorption protocol: Pre-absorb the antibody with yeast lysate from sfh1Δ strains to remove antibodies that bind to irrelevant yeast proteins .

• Signal amplification alternatives: For weak signals, consider using biotin-streptavidin amplification systems rather than increasing antibody concentration, which often increases non-specific binding.

How does phospholipid binding affect epitope accessibility for YKL091C antibody?

Understanding the complex relationship between SFH1's phospholipid binding and antibody detection:

• Conformational change considerations: SFH1 undergoes conformational changes upon phospholipid binding, potentially masking or exposing different epitopes. Multiple antibodies targeting different regions can help detect these changes .

• Detergent impact assessment: Different detergents can selectively extract SFH1 with specific bound phospholipids, affecting epitope accessibility. Compare extraction with different detergents (Triton X-100, digitonin, CHAPS) when troubleshooting inconsistent antibody detection .

• Native vs. denaturing conditions: Compare detection efficiency under native conditions (for immunoprecipitation) versus denaturing conditions (for SDS-PAGE) to identify epitope accessibility issues.

• Mutant analysis strategy: Use SFH1 mutants with altered phospholipid binding properties (such as SFH1 S175I,T177I) to determine how binding affects antibody recognition .

• Phospholipid addition experiments: Add specific phospholipids to purified SFH1 before antibody binding to directly test their effect on epitope accessibility.